United States - English - NLM (National Library of Medicine)

natural health supply - rabies virus (unii: i0v66ki1ld) (rabies virus - unii:i0v66ki1ld) - rabies virus 30 [hp_c] - indications: to be used for acute, self-limiting conditions according to standard homeopathic indications.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - rabies virus inactivated - powder and solvent for suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - rabies virus inactivated - powder and solvent for suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - rabies virus inactivated - powder and solvent for solution for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - rabies virus inactivated - powder and solvent for suspension for injection

United States - English - NLM (National Library of Medicine)

grifols usa, llc - human rabies virus immune globulin (unii: 95f619atq2) (human rabies virus immune globulin - unii:95f619atq2) - human rabies virus immune globulin 300 [iu] in 1 ml - hyperrab is a human rabies immune globulin indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies. limitations of use persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.(1-3) for unvaccinated persons, the combination of hyperrab and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of postexposure prophylaxis.(1-3) beyond 7 days (after the first vaccine dose), hyperrab is not indicated since an antibody response to vaccine is presumed to have occurred. none. risk summary there are no data with hyperrab use in pregnant women to inform a drug-associated risk.  animal reproduction studies have not been conducted with hyperrab.  it is not known whether hyperrab can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  hyperrab should be given to a pregna

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

zoetis belgium sa-nv - rabies virus (inactivated) >= 2 iu/dose - suspension for injection - rabies virus, inactivated - live canine distemper virus + live canine adenovirus + live canine parainfluenza virus + live canine parvovirus + inactivated leptospira - cattle; dog; goat; horse; cat; sheep; other species or species not known; pig

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rabies vaccine, wistar pm/wi 38-1503-3m 3.25 [iu] (target quantity per dose) - powder for injection with diluent - 3.25 iu - active: rabies vaccine, wistar pm/wi 38-1503-3m 3.25 [iu] (target quantity per dose) excipient: albumin hydrochloric acid bme medium - mineral salts, vitamins, amino acids including l-phenylalanine maltose sodium hydroxide sodium chloride water for injection - verorab is indicated for pre-exposure prophylaxis against rabies. verorab is indicated for post-exposure prophylaxis against rabies. verorab should be used in accordance with official local recommendations.

Ireland - English - HPRA (Health Products Regulatory Authority)

zoetis ireland limited - inactivated rabies virus, strain vnukovo-32 - suspension for injection - unknown - rabies virus vaccine - bovine, canine, caprine, equine - food, feline, ferret, ovine, porcine - immunological - inactivated vaccine

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp65 virus - immunologicals - cats - active immunisation of cats 12 weeks of age and older to prevent mortality due to rabies infection.onset of immunity: 4 weeks after the primary vaccination course.duration of immunity after primary vaccination: 1 year.duration of immunity after revaccination: 3 years.